Showing results (271-280 of 303) with videos related to
Sort By:
Pageof 31
BMC Gastroenterology|July 12, 2022
Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-upPaul J Clark, Patricia C Valery, James Ward, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 16, 2025
Palliative and supportive care in patients with hepatocellular carcinoma: a qualitative study on attitudes and perceptions of health professionalsCameron Gofton, Anna Di Bartolomeo, Shalini Wijekulasuriya, et al.Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.Hepatology International|September 22, 2019
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivationTatsuo Kanda, George K K Lau, Lai Wei, et al.JHEP Reports : Innovation in Hepatology|October 18, 2021
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa studyHaiyan Ma, Tien Huey Lim, Apinya Leerapun, et al.Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.Trials|September 24, 2025
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver diseaseLeon A Adams, Deborah de Guingand, Gary P Jeffrey, et al.Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.NEJM Evidence|January 28, 2025
Larsucosterol for the Treatment of Alcohol-Associated HepatitisMitchell Shiffman, Ben Da, Aparna Goel, et al.Pageof 31